{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.189"},{"groupId":"OG001","value":"0.189"},{"groupId":"OG002","value":"0.189"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"description":"Single PK samples were collected at each visit during Part 1 Weeks 2, 4, 6, 8, 10, 12 and at each weekly or monthly visit during Part 2 Weeks 1-12 (Study Weeks 13-37). The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. Ka is defined as the absorption rate constant. This parameter is dose independent, and the population estimate Ka is reported.","groups":[{"description":"Participants who received eltrombopag in Part 1 continued on the same dose in Part 2 unless adjustments were warranted according to the dosing guidelines. Participants who received placebo in Part 1 received Eltrombopag as per age criteria as follows:body weight \\<27 kg received eltrombopag 37.5 mg QD, and those with a body weight \\>=27 kg received eltrombopag 50 mg QD. Participants of East Asian ancestry received a starting dose of eltrombopag 25 mg QD.","id":"OG000","title":"Eltrombopag Cohort 1 (12-17 Years)"},{"description":"Participants who received eltrombopag in Part 1 continued on the same dose in Part 2 unless adjustments were warranted according to the dosing guidelines. Participants who received placebo in Part 1 received Eltrombopag as per age criteria as follows: body weight \\<27 kg received eltrombopag 37.5 mg QD, and those with a body weight \\>=27 kg received eltrombopag 50 mg QD. Participants of East Asian ancestry received a starting dose of eltrombopag 25 mg QD.","id":"OG001","title":"Eltrombopag Cohort 2 (6-11 Years)"},{"description":"Participants who received eltrombopag in Part 1 continued on the same dose in Part 2 unless adjustments were warranted according to the dosing guidelines. Participants who received placebo in Part 1 received Eltrombopag 1.2 mg/kg QD and; participants of East Asian ancestry received a starting dose of eltrombopag 0.8 mg/kg/day.","id":"OG002","title":"Eltrombopag Cohort 3 (1-5 Years)"}],"paramType":"NUMBER","populationDescription":"PK Population. Only those participants who provided pharmacokinetic samples were analyzed","reportingStatus":"POSTED","timeFrame":"Part 1 Weeks 2, 4, 6, 8, 10, 12, and Part 2 Weeks 1-12 (Study Weeks 13 - 37)","title":"Population PK Model Point Estimate for Eltrombopag for Absorption Rate-constant (Ka)","type":"SECONDARY","unitOfMeasure":"1/h"}